Compare · SEAS vs SLNO
SEAS vs SLNO
Side-by-side comparison of SeaWorld Entertainment Inc. (SEAS) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SEAS and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SEAS is the larger of the two at $4.50B, about 1.6x SLNO ($2.76B).
- SLNO has hit the wire 39 times in the past 4 weeks while SEAS has been quiet.
- SEAS has more recent analyst coverage (16 ratings vs 12 for SLNO).
- Company
- SeaWorld Entertainment Inc.
- Soleno Therapeutics Inc.
- Price
- $50.34+2.56%
- $53.02+0.08%
- Market cap
- $4.50B
- $2.76B
- 1M return
- -
- +0.76%
- 1Y return
- -
- -31.78%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- 2014
- News (4w)
- 0
- 39
- Recent ratings
- 16
- 12
SeaWorld Entertainment Inc.
SeaWorld Entertainment, Inc., together with its subsidiaries, operates as a theme park and entertainment company in the United States. The company operates SeaWorld theme parks in Orlando, Florida; San Antonio, Texas; and San Diego, California, as well as Busch Gardens theme parks in Tampa, Florida, and Williamsburg, Virginia. It also operates water park attractions in Orlando, Florida; San Antonio, Texas; Chula Vista, California; Tampa, Florida; and Williamsburg, Virginia. In addition, the company operates a reservations-only theme park in Orlando, Florida and a seasonal park in Langhorne, Pennsylvania. It operates a portfolio of twelve theme parks under the SeaWorld, Busch Gardens, Aquatica, Discovery Cove, Water Country USA, Adventure Island, and Sesame Place brands. The company was formerly known as SW Holdco, Inc. and changed its name to SeaWorld Entertainment, Inc. in December 2012. SeaWorld Entertainment, Inc. was founded in 1959 and is headquartered in Orlando, Florida.
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest SEAS
- SeaWorld San Antonio Reveals Plans for the ALL-NEW Rescue Jr. Hub, a Kid-Friendly World of Discovery Packed with Interactive Play, Immersive Attractions and a One-Of-A-Kind Water Elements - Opening Spring 2025
- Get Ready for Jaw-Dropping Adventures as SeaWorld's Ultimate Shark Experience Returns for 2024
- SeaWorld and Coca-Cola Say Cheers to 60 Years with New Celebration Sundays Featuring Exclusive Merchandise Giveaways for Pass Members and Complimentary Beverage Sampling for All Guests
- SeaWorld Unveils 60th Anniversary Celebration Plans for 2024
- SeaWorld Entertainment Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form SC 13G filed by SeaWorld Entertainment Inc.
- SEAWORLD ENTERTAINMENT, INC. ANNOUNCES FOURTH QUARTER AND FISCAL 2023 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION
- Splash Beverage Partners With Sea World Parks & Entertainment; Pulpoloco Sangria Available At Venues
- SeaWorld Launches 60th Anniversary Celebrations and Unveils "There's So Much More to Sea"
- SeaWorld Entertainment Changes Corporate Name To United Parks & Resorts
Latest SLNO
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Manning Meredith returned 64,507 shares to the company, closing all direct ownership in the company (SEC Form 4)